Low-Dose Aspirin Daily: Cardiovascular Benefits and Latest Trial Data
Low-dose aspirin daily, typically 81 mg, reduces cardiovascular events in selected adults by inhibiting platelet aggregation. The ARRIVE trial, published in 2018, showed a modest reduction in first heart attacks among men but no significant benefit for women in primary prevention. The ASPREE trial, released in 2018, found that aspirin daily increased all-cause mortality in older adults without prior cardiovascular disease, driven largely by cancer and bleeding deaths. Current guidelines from the American Heart Association emphasize risk stratification before initiating therapy, and the U.S. Preventive Services Task Force updated its recommendation in 2022 to narrow the age range for primary prevention. For investors, companies like Bayer and generic manufacturers continue to see steady demand as the market shifts toward precision-based prescribing. Forbes analysis on aspirin and heart health
Key Cardiovascular Outcomes and Real-World Impact
Meta-analyses of randomized trials confirm that low-dose aspirin daily reduces the relative risk of myocardial infarction by about 15% in high-risk primary prevention populations, with a number needed to treat of approximately 1,000 over five years. The annual cost of generic 81 mg aspirin is under $10 in the United States, making it one of the cheapest preventive therapies available. However, the absolute benefit shrinks in adults over 70, where baseline bleeding risk rises sharply. Health systems and insurers increasingly use risk calculators to identify the narrow subgroup where daily aspirin yields net benefit. WHO cardiovascular disease fact sheet
Bleeding Risks, Gastrointestinal Safety, and Risk Mitigation Strategies
The most serious adverse effect of low-dose aspirin daily is gastrointestinal bleeding, with a pooled risk ratio of 1.5 to 2.0 compared with placebo across major trials. The risk escalates with age, concurrent use of nonsteroidal anti-inflammatory drugs, and history of peptic ulcer disease. Enteric-coated formulations do not meaningfully reduce upper GI bleeding, as aspirin's antiplatelet effect occurs systemically. Proton pump inhibitors such as omeprazole lower bleeding risk when co-prescribed, a strategy recommended by the American College of Gastroenterology. FDA advisory committee materials on OTC aspirin safety
Risk Stratification and Clinical Decision Tools
Clinicians use the ASCVD risk estimator and bleeding risk scores to weigh the net benefit of low-dose aspirin daily before prescribing. The ASPREE trial demonstrated that adults aged 70 and older experienced a higher rate of major hemorrhage than those on placebo, shifting the risk-benefit balance against routine use in the elderly. Patients with diabetes and no prior cardiovascular events show a less clear benefit, with the ADA and AHA jointly recommending against aspirin for primary prevention in most adults with diabetes under 50. ACC summary of the ARRIVE trial
Market Landscape, Regulatory Status, and Economic Considerations
The global low-dose aspirin market is dominated by generic manufacturers, with Bayer's buffered and enteric-coated brands holding a leading share in